BBIOBridgeBio Pharma, Inc.
82.51USD-1.72%Mkt Cap: 16.41B $P/E:

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR sta…

Key Statistics

Company
Market Cap16.41B $
Enterprise Value18.88B $
Revenue (TTM)713.07M $
Gross Profit481.11M $
Net Income (TTM)-724.93M $
Revenue/Share3.675 USD
Last Price82.51 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees999
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS10806X1028
Valuation
P/E (Trailing)
P/E (Forward)541.45
PEG
EV/EBITDA-39.93
EV/Revenue26.47
P/S22.74
P/B-6.44
EPS (TTM)-3.52
EPS (Forward)0.15
52W Range
46.8177% of range93.42
52W High93.42 USD
52W Low46.81 USD
Profitability
Gross Margin95.82%
Oper. Margin-43.94%
EBITDA Margin-66.30%
Profit Margin-144.39%
ROE34.74%
ROA-77.45%
Growth
Revenue Growth120.40%
Earnings Growth
Cash Flow & Leverage
Operating CF-445.91M $
CapEx (TTM)9.59M $
FCF Margin-44.91%
FCF Yield-1.95%
Net Debt2.65B $
Net Debt/EBITDA-5.61
Balance Sheet
Debt/Equity-0.89
Current Ratio1.23
Quick Ratio1.09
Book Value/Sh-12.8800 USD
Cash/Share3.684 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)108.43 USD
Upside (mean)+31.4%
Target Range80.00 USD157.00 USD
$80.00+31.4% to mean$157.00
# Analysts21
Ownership
Shares Out.195.49M
Float167.15M
Insiders3.93%
Institutions99.38%
Short Interest
Short Ratio7.0d
Short % Float13.35%
Short % Out.11.95%
Shares Short23.34M
Short (prev mo.)24.10M
Technical
SMA 5078.39 (+5.3%)
SMA 20073.08 (+12.9%)
Beta0.98
S&P 52W Chg18.16%
Avg Vol (30d)2.87M
Avg Vol (10d)2.62M
Technical Indicators
RSI (14)57.5
MACD0.9422
MACD Signal1.4498
MACD Hist.-0.5076
BB Upper86.15 USD
BB Middle82.67 USD
BB Lower79.20 USD
BB Width8.40%
ATR (14)3.196 USD
Vol Ratio (20d)1.36x